

# Genetic testing: oncology - molecular analysis of solid tumors and hematologic malignancies

These services may or may not be covered by your HealthPartners plan. Please see your plan documents for your specific coverage information. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage.

#### **Administrative Process**

#### Prior authorization is required for the following services:

- Molecular Profiling Panel Testing of Solid Tumors and Hematologic Malignancies
- Single Gene Testing of Solid Tumors and Hematologic Malignancies, unless stated below as prior authorization not required
- HLA Typing For Transplantation
- Red Blood Cell Genotyping in Multiple Myeloma
- Tumor Mutational Burden (TMB) Testing
- Measurable (Minimal) Residual Disease (MRD) Analysis
- Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests
- Testing that is associated with a procedure code listed in "Box A", below.

#### Prior authorization is not required for the following services:

- Tumor Specific BCR/ABL Kinase Domain Analysis
- Myeloproliferative Neoplasms (MPNs) Panel Tests
- Tumor Specific MPL Variant Analysis
- Tumor Specific CEBPA Variant Analysis (81218)
- Tumor Specific FLT3 Variant Analysis
- Tumor Specific IGHV Variant Somatic Hypermutation Analysis
- Tumor Specific KIT Variant Analysis (81272, 81273)
- Tumor Specific MGMT Methylation Analysis
- Tumor Specific Microsatellite Instability (MSI) Analysis
- Tumor Specific PIK3CA Variant Analysis
- Tumor Specific NPM1 Variant Analysis
- Tumor Specific IDH1 and IDH2 Variant Analysis

# The following genetic tests are considered investigational/experimental and, therefore, not covered:

- Cancer Exome and Genome Sequencing in Solid Tumors and Hematologic Malignancies
- Genetic Testing to Confirm the Identity of Laboratory Specimens

**Prior authorization is sometimes required for certain codes.** Refer to the list in Related Content to find out whether prior authorization is required for a specific indication. Prior authorization requirements are based on both the procedure code (CPT) and primary diagnosis code (ICD-10-CM) associated with the genetic testing.

# Prior authorization is not required for Targeted testing related to solid tumors and hematological malignancies when it is associated with both:

- a primary diagnosis code from the list in related content, and
- a procedure code from the list in related content

Tests that require prior authorization will be reviewed for medical necessity of the testing as a whole. That is, a single coverage decision will apply to all of the tests, services, and/or procedure codes associated with the genetic test, whether they are requested/billed together or separately.

#### Box A: Genetic testing procedure codes that require prior authorization


Molecular pathology procedures, Tier 2 or unlisted (CPT 81400-81408, 81479)

Unlisted multianalyte assays (CPT 81599)


Any other listed or unlisted laboratory/pathology CPT code when it is used in association with a genetic test

#### **Policy Reference Table**


If available, codes are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all-inclusive.




Coverage Criteria Sections		Example Tests (Labs)	Common CPT Codes	Common ICD Codes	
Molecular Profiling Pan	el Tes	sting of Solid Tumors and Hematolog	ic Malignancies		
Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels	Foun	dationOne CDx (Foundation Medicine)	0037U	C00-D49, Z85	
	MSK-IMPACT (Memorial Sloan Kettering Medical Center)		0048U		
		omap ExTra (Exact Sciences ratories, LLC)	0329U		
	OnkoSight Advanced Solid Tumor NGS Panel (BioReference Labs)		81445, 81455, 81457, 81458		
	Preci	se Tumor (Myriad)			
	Temp	ous xT (Tempus)	0473U		
	Guar	dant360 TissueNext (Guardant)	0334U		
		x elio tissue complete (Personal ome Diagnostics, Inc)	0250U		
	Omn	iSeq INSIGHT (Labcorp)	81459		
	Temp (Tem	ous xT with PD-L1 IHC, MMR IHC pus)			
		Tumor Expanded Panel (Quest nostics)	0379U		
		OncoPlex Cancer Gene Panel rersity of Washington)	81459		
	Strat	a Select (Strata Oncology)	0391U		
Targeted RNA Fusion Panels		eted Solid Tumor NGS Fusion Panel Genomics)	81449	C91, C34, C71, C49, C96	
Broad RNA Fusion Panel Tests		ous xR Whole Transcriptome RNA encing (Tempus)	81456	C00-C80	
	Aven	ta FusionPlus (Aventa Genomics)	0444U		
Broad Molecular Profiling Panels for	Foun Medi	dationOne Heme (Foundation cine)	81450, 81455	C91, C92, D46.9	
Hematologic Malignancies and Myeloid Malignancy	Temp (Tem	ous xT Hematologic Malignancy pus)			
Panels		Comprehensive - Myeloid Disorders Genomics Laboratories)			
	Com	oComplete Myeloid Neoplasms prehensive OncoHeme Next- eration Sequencing, Varies (Mayo c Laboratories)	81450		
		osight Advanced NGS Myeloid Panel Reference Laboratories)			
Colorectal Cancer Focused Molecular		n Cancer Mutation Panel (Ohio State ersity Molecular Pathology Lab)	81445	C18-C20	
Profiling Panels	COL	ONSEQPlus Panel (MedFusion)	81457		
Lung Cancer Focused Molecular Profiling	Onco Scier	omine Dx Target Test (Thermo Fisher ntific)	0022U	C34	
Panels		Sight Advanced Lung Cancer NGS Il (Bioreference Laboratories)	81457		
	Lung	HDPCR (Protean BioDiagnostics)	0478U		




<u> </u>				
Cutaneous Melanoma	MelanomaSeqPlus (Quest Diagnostics)	81445	C43, D03	
Focused Molecular Profiling Panels	OnkoSight Advanced Melanoma Panel NGS (Bioreference Laboratories)	81457		
Acute Myeloid Leukemia (AML) Focused Molecular Profiling Panels	MyAML Gene Panel Assay (Laboratory for Personalized Molecular Medicine)	0050U	C92, D47	
	NeoTYPE AML Prognostic Profile (NeoGenomics)	81450		
	LeukoVantage, Acute Myeloid Leukemia (AML) (Quest Diagnostics)			
Myeloproliferative Neoplasms (MPNs) Panel	Myeloproliferative Neoplasm, JAK2 V617F with Reflex to CALR and MPL, Varies (Mayo Medical Laboratories)	81206, 81207, 81208, 81219, 81270, 81279, 81338, 81339	D47	
	OnkoSight Advanced NGS JAK2, MPL, CALR Panel (BioReference Laboratories)			
Single Gene Testing of	Solid Tumors and Hematologic Malignanc	ies		
Tumor Specific BCR/ABL Kinase Domain Analysis	ABL1 Kinase Domain Mutation Analysis (NeoGenomics)	81170	C91, C92	
	Onkosight NGS ABL1 Sequencing (BioReference Laboratories)			
Tumor Specific BCR/ABL FISH, Qualitative and Quantitative Tests	BCR/ABL1 Gene Rearrangement, Quantitative, PCR (Quest Diagnostics)	81206, 81207, 81208	C83, C85, C91.00- C91.02, C92.0 – C92.12, D45, D47, D47.1, D47.3, D69.3	
	BCR-ABL1 Transcript Detection for Chronic Myelogenous Leukemia (CML) and Acute Lymphocytic Leukemia (ALL), Quantitative (Labcorp)			
	BCR-ABL1 (t(9;22)) RNA Quantitative with Interpretation (University of Iowa Hospitals and Clinics – Department of Pathology)	0016U		
	MRDx BCR-ABL Test (MolecularMD)	0040U		
	Detection by FISH of t(9;22) BCR/ABL (CGC Genetics)			
	BCR/ABL t(9;22) (NeoGenomics Laboratories)	81479, 88271, 88274, 88275, 88291		
	BCR ABL Qualitative (Cincinnati Children's Hospital)			
Tumor Specific <i>BRAF</i> Variant Analysis	BRAF Mutation Analysis (NeoGenomics)	81210	C18-C21, C34, C43, C71, C73, C91.4	
Tumor Specific BRCA1/2 Variant Analysis	BRCA1/2 Mutation Analysis, NGS, Tumor (Mayo Clinic Laboratories)	81162, 81163, 81164, 81165, 81166, 81167, 81216	C56, C61	
	BRCA1/2 Mutation Analysis for Tumors (NeoGenomics Laboratories)			
Tumor Specific <i>CALR</i> Variant Analysis	Calreticulin (CALR) Mutation Analysis (Quest Diagnostics)	81219	C94, D47.1	
Tumor Specific CEBPA Variant Analysis	CEBPA Mutation Analysis (Labcorp)	81218	C92	
Tumor Specific <i>EGFR</i> Variant Analysis	EGFR Mutation Analysis (NeoGenomics Laboratories)	81235	C34	
Tumor Specific ESR1 Variant Analysis	ESR1 Mutations Analysis, NGS, Tumor (Mayo Clinic Laboratories)	81479	C50	



* *				
Tumor Specific <i>FLT3</i> Variant Analysis	FLT3 ITD and TKD Mutation (PCR) (PathGroup)	81245, 81246	C92	
	LeukoStrat CDx FLT3 Mutation Assay (Versiti)	0023U		
	FLT3 ITD MRD Assay (Laboratory for Personalized Molecular Medicine)	0046U		
Tumor Specific <i>IDH1</i> and <i>IDH2</i> Variant Analysis	IDH1/IDH2 Mutation Analysis by PCR (NeoGenomics)	81120, 81121	C71, C92, D49.6	
	IDH1, IDH2, and TERT Mutation Analysis, Next Generation Sequencing, Tumor (IDTRT) (Mayo Clinic)	0481U		
Tumor Specific <i>IGHV</i> Somatic Hypermutation Analysis	IgHV Mutation Analysis (NeoGenomics)	81261, 81262, 81263	C83, C91, D47.Z1	
Tumor Specific <i>JAK2</i> Variant Analysis	JAK2 Exon 12 to 15 Sequencing, Polycythemia Vera Reflex, Varies (Mayo Clinic Laboratories)	0027U	C91, C92, C94, D45, D47.1, D47.3, D75.81	
	JAK2 Mutation (University of Iowa)	0017U		
	JAK2 V617F Mutation Analysis (Quest Diagnostics)	81270	1	
Tumor Specific KIT	KIT Mutation Analysis (ProPath)	81272, 81273	C43, C49.A, C92,	
Variant Analysis	KIT (D816V) Digital PCR in Systemic Mastocystosis (Labcorp)		D47.1, D47.02	
Tumor Specific <i>KRAS</i> Variant Analysis	KRAS Mutation Analysis (NeoGenomics)	81275, 81276	C18-21, C34	
Tumor Specific MGMT Methylation Analysis	MGMT Promoter Methylation - Tumor (Ohio State University Molecular Laboratory)	81287	C71	
Tumor Specific <i>MLH1</i> Methylation Analysis	MLH1 Promoter Methylation Analysis (NeoGenomics)	81288	C18-C21, C54.1	
Tumor Specific <i>MPL</i> Variant Analysis	MPL Mutation Analysis (Quest Diagnostics)	81338, 81339	D45, D47.1, D47.3, D75.81	
Tumor Specific Microsatellite Instability	Microsatellite Instability (MSI) by PCR (NeoGenomics)	81301	C15-C23, C50, C53, C54.1, C62, C80	
(MSI) Analysis	Microsatellite Instability (MSI) (Quest Diagnostics)			
Tumor Specific NPM1 Variant Analysis	NPM1 MRD Assay (Laboratory for Personalized Molecular Medicine	0049U	C92	
	Onkosight NGS NPM1 Sequencing (BioReference Laboratories)	81310		
Tumor Specific NRAS Variant Analysis	NRAS Mutation Analysis (NeoGenomics)	81311	C18-C21	
Tumor Specific <i>PIK3CA</i> Variant Analysis	PIK3CA Mutation Analysis (Quest Diagnostics)	81309	C50, C55	
	PIK3CA Mutation Analysis, therascreen - QIAGEN (Labcorp)	0155U		
Tumor Specific <i>TP53</i> Variant Analysis	TP53 Mutation Analysis (NeoGenomics Laboratories)	81352	C92, R71, R79	
HLA Typing for Transpl	antation			
	HLA-A,B Intermediate Resolution (Versiti)			



<b>*</b> *				
HLA Typing for Transplantation	HLA-B Low Resolution (Versiti)	81370, 81371, 81372, 81373	C25, C81-C96, D46, D61, Z52.20, Z52.3,	
	HLA-DQB1,DQA1 Intermediate Resolution (Versiti)	81376	Z52.4 Z52.89, N17, N18, N19, I12, E08- E13	
	HLA-A, B, C, DRB1 and DQ High Resolution (Quest)	81378		
	HLA A,B,C Profile (High Resolution) (Labcorp)	81379		
	HLA-A High Resolution (Versiti)	81380		
	HLA High Resolution Panel by NGS (Versiti)	81378, 81382	]	
Measurable (Minimal) R	esidual Disease (MRD) Analysis			
Hematologic (Minimal) Residual Disease (MRD) Testing	MyMRD NGS Panel Assay (Laboratory for Personalized Molecular Medicine)	0171U	C91, R71, R79	
	ClonoSEQ Assay (Adaptive Biotechnologies)	0364U		
Evidence-Based Solid Tumor Minimal Residual	Signatera - Residual Disease Test (MRD) - (Natera)	0340U	C00-D49, Z85	
Disease (MRD) Testing	Guardant Reveal (Guardant Health)	81479		
	Guardant360 Response (Guardant Health)	0422U		
Emerging Evidence Solid Tumor Minimal Residual Disease (MRD) Testing	COLVERA (Clinical Genomics Pathology, Inc.)	0229U		
	Invitae Personalized Cancer Monitoring - Baseline Test and Monitoring Test (Invitae)	0306U, 0307U		
	Northstar Response (BillionToOne)	0486U		
	OptiSeq Colorectal Cancer NGS Panel (DiaCarta Inc.)	0498U		
	QuantiDNA Colorectal Cancer Triage Test (DiaCarta Inc.)	0501U		
HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing	NavDx (Naveris)	0356U	C10.9	
Tumor Mutational Burd	en (TMB)			
Tumor Mutational Burden (TMB)	Tumor Mutational Burden (MedFusion)	81479	C00-D49, Z85	
Red Blood Cell Genoty	ping in Multiple Myeloma			
Red Blood Cell	PreciseType HEA (Immucor)	0001U	C90.0, R71, R79	
Genotyping in Multiple Myeloma	Navigator ABO Sequencing (Grifols Immunohematology Center)	0180U		
	Navigator ABO Blood Group NGS (Grifols Immunohematology Center)	0221U		
Cancer Exome and Ger	nome Sequencing	•	•	
Cancer Exome and Genome Sequencing	Praxis Somatic Whole Genome Sequencing (Praxis Genomics)	0297U	C00-D49, Z85	
	Cancer Whole Exome Sequencing with Transcriptome (Columbia University - Personalized Genomic Medicine)	81415, 81416, 81425, 81426		
	Tempus xE (Tempus)	]		
		I .	i	



	EXaCT-1 Whole Exome Testing (Weill Cornell Medicine)	0036U	
Genetic Testing to Confirm the Identity of Laboratory Specimens			
	know error DNA Specimen Provenance Assay (DSPA) (Strand Diagnostics, LLC)	81265, 81266, 81479	C00.0-D49

CPT Copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

# Coverage

# Molecular Profiling Panel Testing of Solid Tumors and Hematologic Malignancies Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels

- 1. Tumor-type agnostic solid tumor molecular profiling panels are considered **medically necessary** when:
  - A. The member meets both of the following:
    - i. The member has a diagnosis of:
      - a) Recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, or
      - b) Histiocytosis, or
      - c) Non-small cell lung cancer (NSCLC) regardless of stage, or
      - d) Resectable or borderline resectable pancreatic adenocarcinoma, or
      - e) Central nervous system tumor, and
    - ii. The member is seeking further cancer treatment (e.g., therapeutic chemotherapy), **or**
  - B. The member meets one of the following:
    - i. The member has a diagnosis of uterine neoplasm, and
      - a) The member is undergoing initial evaluation, or
    - ii. The member has a gastrointestinal stromal tumor, and
      - The tumor is negative for KIT and PDGFRA mutations.
- 2. Repeat testing via a tumor-type agnostic solid tumor molecular profiling panel is considered **medically necessary** when:
  - A. The member has progression of:
    - i. Advanced or metastatic non-small cell lung cancer (NSCLC), or
    - ii. Advanced or metastatic gastric adenocarcinoma, or
    - iii. Metastatic prostate cancer.
- 3. Tumor-type agnostic solid tumor molecular profiling panels are considered investigational for all other indications.

Note: Additional codes representing additional IHC and/or cytogenetics analyses may be billed alongside the PLA or GSP codes.

Back to top


#### **Targeted RNA Fusion Panels**

- 1. RNA specific fusion panels with 5-50 genes performed on peripheral blood, bone marrow or solid tumors are considered **medically necessary** when:
  - A. The member has a diagnosis of or is undergoing workup for:
    - i. Adult or pediatric acute lymphoblastic leukemia (ALL), or
    - ii. Glioma, or
    - iii. Histiocytosis, or
    - iv. Sarcoma, or
  - B. The member has a gastrointestinal stromal tumor, and
    - i. The tumor is negative for KIT and PDGFRA somatic mutations, or
  - C. The member has non-small cell lung cancer, and
    - i. DNA based NGS tumor profiling was negative for actionable mutations, or
  - D. The member has a metastatic or advanced solid tumor, and
    - i. There is a fusion-targeted therapy with regulatory approval for that cancer type, or
    - ii. DNA-based panel testing was negative for oncogenic driver mutations.
- 2. RNA specific fusion panels are considered **investigational** for all other indications.

Back to top

#### **Broad RNA Fusion Panels**

1. RNA fusion panels with 51 or more genes utilizing RNA analysis alone are considered **medically necessary** when:



- A. The member has a diagnosis of adult or pediatric acute lymphoblastic leukemia (ALL).
- 2. RNA fusion panel tests with 51 or more genes utilizing RNA analysis alone are considered **investigational** for all other indications.

Back to top

# Broad Molecular Profiling Panels For Hematologic Malignancies and Myeloid Malignancy Panels

- 1. Broad molecular profiling panels for hematologic malignancies and myeloid malignancy panels in bone marrow or peripheral blood are considered **medically necessary** when:
  - A. The member is undergoing evaluation for acute myeloid leukemia (AML), or
  - B. The member has newly diagnosed acute lymphoblastic leukemia (ALL), or
  - C. The member has newly diagnosed myelodysplastic syndrome (MDS), or
  - D. The member has suspected myelodysplastic syndrome (MDS), and
    - i. Other causes of cytopenia(s) have been ruled out, or
  - E. The member is suspected to have a myeloproliferative neoplasm (MPN), and
    - i. This is the member's initial genetic evaluation for suspected MPN, or
    - ii. Previous results of JAK2, CALR, and MPL analysis were negative, or
  - F. The member has a diagnosis of chronic myelogenous leukemia (CML), and
    - i. There has been progression to accelerated or blast phase, or
    - ii. Results of *BCR-ABL1* kinase domain mutation analysis were negative.
- 2. Repeat broad molecular profiling panels for hematologic malignancies and myeloid malignancy panels in bone marrow or peripheral blood are considered **medically necessary** when:
  - A. The member has myelodysplastic syndrome (MDS), and
    - . The member has relapsed after allo-HCT (hematopoietic cell transplant), or
  - B. The member has acute lymphoblastic leukemia (ALL), and
    - i. The member is showing evidence of symptomatic relapse after maintenance therapy, **or**
  - C. The member has acute myeloid leukemia (AML), and
    - i. The member has relapsed or refractory disease or progression on treatment.
- 3. Broad molecular profiling panels for hematologic malignancies and myeloid malignancy panels in bone marrow or peripheral blood are considered **investigational** for all other indications.

**Note:** If a multigene panel is performed, appropriate panel codes should be used. These clinical criteria are not intended to address liquid biopsies.

Back to top

# **Colorectal Cancer Focused Molecular Profiling Panels**

- Colorectal cancer focused molecular profiling panels in solid tumors are considered medically necessary when:
  - A. The member has suspected or proven metastatic colorectal cancer, **and**
  - B. The panel contains at a minimum the following genes: KRAS, NRAS, BRAF.
- 2. Colorectal cancer-focused molecular profiling panels are considered **investigational** for all other indications.

Note: If a panel is performed, appropriate panel codes should be used.

Back to top

#### **Lung Cancer Focused Molecular Profiling Panels**


- 1. Lung cancer focused molecular profiling panels are considered **medically necessary** when:
  - A. The member has a diagnosis of any of the following:
    - i. Advanced (stage IIIb or higher) or metastatic lung adenocarcinoma, or
    - ii. Advanced (stage IIIb or higher) or metastatic large cell lung carcinoma, **or**
    - iii. Advanced (stage IIIb or higher) or metastatic squamous cell lung carcinoma, or
    - iv. Advanced (stage IIIb or higher) or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **and**
  - The member is seeking further cancer treatment (e.g., therapeutic chemotherapy).
- 2. Repeat lung cancer-focused molecular profiling panels are considered **medically necessary** when the member has progression on targeted therapy for non-small cell lung cancer.
- 3. Lung cancer-focused molecular profiling panels are considered **investigational** for all other indications.

**Note:** If a panel is performed, appropriate panel codes should be used.

Back to top

#### **Cutaneous Melanoma Focused Molecular Profiling Panels**

- 1. Cutaneous melanoma focused molecular profiling panels are considered **medically necessary** when:
  - A. The member has a diagnosis of one of the following:
    - i. Stage III melanoma or higher, or
    - ii. Recurrent melanoma, and
  - B. The member is seeking further cancer treatment (e.g., therapeutic chemotherapy), and



- C. One of the following:
  - i. The member has not had previous somatic testing via a multigene cancer panel for the same primary melanoma diagnosis, **or**
  - ii. The member **has** had previous somatic testing via a multigene cancer panel for a primary melanoma diagnosis and has a **new** primary melanoma diagnosis for which this testing is being ordered.
- 2. Cutaneous melanoma focused molecular profiling panels are considered **investigational** for all other indications.

Note: If a panel is performed, appropriate panel codes should be used.

Back to top

#### Acute Myeloid Leukemia (AML) Focused Molecular Profiling Panels

- 1. Acute myeloid leukemia focused molecular profiling panels for the diagnosis or evaluation of acute myeloid leukemia (AML) are considered **medically** necessary when:
  - A. The member has a suspected or confirmed diagnosis of acute myeloid leukemia (AML).
- 2. Acute myeloid leukemia focused molecular profiling panels for the diagnosis or evaluation of acute myeloid leukemia (AML) are considered **investigational** for all other indications.

Note: If a multigene panel is performed, appropriate panel codes should be used.

Back to top

### Myeloproliferative Neoplasms (MPNs) Panels

- Myeloproliferative neoplasm (MPN) molecular profiling panels are considered medically necessary when:
  - A. The member is suspected to have a myeloproliferative neoplasm (i.e., polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia), **and**
  - B. The panel includes, at a minimum, testing of the following genes: JAK2, CALR, and MPL.
- 2. Myeloproliferative neoplasm (MPN) molecular profiling panels are considered **investigational** for all other indications.

Back to top

# Single-Gene Testing of Solid Tumors and Hematologic Malignancies Tumor Specific *BCR/ABL1* Kinase Domain Analysis

- 1. Tumor specific *BCR/ABL1* kinase domain analysis in hematologic malignancies is considered **medically necessary** when:
  - A. The member has a diagnosis of any of the following:
    - i. Chronic myeloid leukemia (CML), or
      - Ph-positive acute lymphocytic leukemia (ALL), and
  - B. The member has any of the following:
    - i. Inadequate initial response to TKI therapy, **or**
    - ii. Loss of response to TKI therapy, or
    - iii. Disease progression to the accelerated or blast phase, or
    - iv. Relapsed/refractory disease.

Back to top


#### Tumor Specific BCR/ABL1 FISH, Qualitative, or Quantitative Tests

- 1. Tumor specific *BCR/ABL1* FISH, qualitative, or quantitative tests in hematologic malignancies is considered **medically necessary** when:
  - A. The member is suspected to have a myeloproliferative neoplasm (i.e., polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia), **or**
  - B. The member is undergoing diagnostic workup for:
    - i. Acute lymphoblastic leukemia (ALL), or
    - ii. Acute myeloid leukemia (AML), or
    - iii. Chronic myelogenous leukemia (CML), or
    - iv. B-cell lymphoma, or
  - C. The member is undergoing monitoring of disease progression (i.e., for minimal residual disease (MRD) monitoring using a quantitative test only) for:
    - i. Acute lymphoblastic leukemia (ALL), or
    - ii. Acute myeloid leukemia (AML), or
    - iii. Chronic myelogenous leukemia (CML), or
    - iv. B-cell lymphoma.

Back to top

# Tumor Specific BRAF Variant Analysis

- 1. Tumor specific *BRAF* variant analysis in solid tumors and hematologic malignancies is considered **medically necessary** when:
  - A. The member has a diagnosis of:
    - i. Suspected or proven metastatic colorectal cancer, or
    - ii. Advanced or metastatic non-small-cell lung cancer (NSCLC), or



- iii. Stage III or stage IV cutaneous melanoma, or
- iv. Indeterminate thyroid nodules requiring biopsy, or
- v. Anaplastic thyroid carcinoma, **or**
- vi. Locally recurrent, advanced and/or metastatic papillary thyroid cancer, or
- vii. Locally recurrent, advanced and/or metastatic follicular thyroid cancer, or
- viii. Locally recurrent, advanced and/or metastatic Hurthle cell thyroid carcinoma, or
- ix. Low-grade glioma or pilocytic astrocytoma, or
- x. Resectable or borderline resectable, or locally advanced/metastatic pancreatic adenocarcinoma, **or**
- xi. Metastatic small bowel adenocarcinoma, or
- xii. Locally advanced, recurrent or metastatic esophageal or esophagogastric junction cancer, **or**
- xiii. Locally advanced, recurrent or metastatic gastric cancer, or
- B. The member is being evaluated for:
  - i. Hairy cell leukemia (for individuals without cHCL [classical hairy cell leukemia] immunophenotype), **or**
  - Histiocytosis (Langerhans cell histiocytosis or Erdheim-Chester disease).

Back to top

#### Tumor Specific BRCA1/2 Variant Analysis

- 1. Tumor specific BRCA1/2 variant analysis in solid tumors is considered medically necessary when:
  - A. The member has a diagnosis of:
    - i. Ovarian, fallopian tube and/or primary peritoneal cancer, or
    - ii. Metastatic prostate cancer, or
    - iii. Resectable, borderline resectable, or locally advanced / metastatic pancreatic cancer.

Back to top

#### Tumor Specific CALR Variant Analysis

- 1. Tumor specific *CALR* variant analysis is considered **medically necessary** when:
  - A. The member is suspected to have a myeloproliferative neoplasm (i.e., polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia), **or**
  - B. The member is suspected to have a myelodysplastic syndrome (MDS).

Back to top

#### Tumor Specific CEBPA Variant Analysis

- 1. Tumor specific *CEBPA* variant analysis in hematologic malignancies is considered **medically necessary** when:
  - A. The member is undergoing evaluation for acute myeloid leukemia (AML).

Back to top

#### Tumor Specific EGFR Variant Analysis

- 1. Tumor specific *EGFR* variant analysis in solid tumors is considered **medically necessary** when:
  - A. The member has a diagnosis of:
    - i. Stage IB or higher lung adenocarcinoma, or
    - ii. Stage IB or higher large cell lung carcinoma, or
    - iii. Stage IB or higher squamous cell lung carcinoma, or
    - iv. Stage IB or higher non-small cell lung cancer (NSCLC) not otherwise specified (NOS).

Back to top

#### **Tumor Specific ESR1 Variant Analysis**

- Tumor specific ESR1 variant analysis in solid tumors is considered **medically necessary** when:
  - A. The member is one of the following:
    - i. Pre-menopausal female receiving ovarian ablation or suppression, or
    - ii. Postmenopausal female, or
    - iii. Adult male, and
  - B. The member has a diagnosis of ER-positive and HER2-negative breast cancer, **and**
  - C. The member has disease progression after one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.

Back to top

#### Tumor Specific FLT3 Variant Analysis

- 1. Tumor specific *FLT3* variant analysis in hematologic malignancies is considered **medically necessary** when:
  - A. The member has suspected or confirmed acute myeloid leukemia (AML), or
  - B. The member has a diagnosis of:
    - i. Acute lymphocytic leukemia (ALL), or
    - ii. Myelodysplastic syndrome (MDS), or



iii. Myeloproliferative neoplasm.

Back to top

#### Tumor Specific IDH1 and IDH2 Variant Analysis

- 1. Tumor specific *IDH1* and *IDH2* variant analysis in solid tumors or hematologic malignancies is considered **medically necessary** when:
  - A. The member has a diagnosis of:
    - i. Glioma, or
    - ii. Acute myeloid leukemia (AML).

Back to top

#### Tumor Specific IGHV Variant Somatic Hypermutation Analysis

- 1. Tumor specific *IGHV* somatic hypermutation analysis in hematologic malignancies is considered **medically necessary** when:
  - A. The member is undergoing work up for or has a diagnosis of:
    - i. Chronic lymphocytic leukemia (CLL), or
    - ii. Small lymphocytic leukemia (SLL), or
    - iii. Primary cutaneous B-cell lymphoma, or
    - iv. B-cell lymphoma.

Back to top

#### Tumor Specific JAK2 Variant Analysis

- 1. Tumor specific *JAK2* variant analysis in solid tumors or hematologic malignancies is considered **medically necessary** when:
  - A. The member is suspected to have a myeloproliferative neoplasm (MPN) (i.e., polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia). **or**
  - B. The member has acute lymphoblastic leukemia (ALL), **or**
  - C. The member is suspected to have a myelodysplastic syndrome (MDS).

Back to top

#### Tumor Specific KIT Variant Analysis

- 1. Tumor specific KIT variant analysis in solid tumors or hematologic malignancies is considered **medically necessary** when:
  - A. The member is being evaluated for systemic mastocytosis, **or**
  - B. The member has a diagnosis of acute myeloid leukemia (AML), or
  - C. The member has stage IV cutaneous melanoma, or
  - D. The member has a suspected or confirmed gastrointestinal stromal tumor (GIST).

Back to top

#### Tumor Specific KRAS Variant Analysis

- 1. Tumor specific *KRAS* variant analysis in solid tumors is considered **medically necessary** when:
  - A. The member has suspected or proven metastatic colorectal cancer, **or**
  - B. The member is undergoing workup for metastasis of non-small cell lung cancer, **or**
  - C. The member has resectable, borderline resectable or locally advanced/metastatic pancreatic adenocarcinoma,  ${\bf or}$
  - D. The member has unresectable or metastatic gallbladder cancer, **or**
  - E. The member has unresectable or metastatic intrahepatic or extrahepatic cholangiocarcinoma.

Back to top

# **Tumor Specific MGMT Methylation Analysis**

- 1. Tumor specific *MGMT* promoter methylation analysis in solid tumors is considered **medically necessary** when:
  - A. The member has a diagnosis of:
    - i. High grade (stage III or IV) anaplastic oligodendroglioma, or
    - ii. High grade (stage III or IV) anaplastic astrocytoma, or
    - iii. High grade (stage III or IV) anaplastic glioma, or
    - iv. High grade (stage III or IV) glioblastoma.


Back to top

#### Tumor Specific MLH1 Methylation Analysis

- 1. Tumor specific *MLH1* promoter methylation analysis in solid tumors is considered **medically necessary** when:
  - A. The member has a diagnosis of any of the following:
    - i. Colorectal cancer, or
    - ii. Endometrial (uterine) cancer, and
  - B. Previous tumor testing showed loss of *MLH1* on immunohistochemistry analysis.

Back to top

# Tumor Specific MPL Variant Analysis



- 1. Tumor specific *MPL* variant analysis in hematologic malignancies is considered **medically necessary** when:
  - A. The member is suspected to have a myeloproliferative neoplasm (MPN) (i.e., polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia), **or**
  - B. The member is suspected to have a myelodysplastic syndrome (MDS).

Back to top

#### Tumor Specific Microsatellite Instability (MSI) Analysis

- 1. Tumor specific microsatellite instability (MSI) analysis in solid tumors is considered **medically necessary** when:
  - A. The member has a diagnosis of:
    - i. Colorectal cancer, or
    - ii. Endometrial cancer, or
    - iii. Gastric cancer, or
    - iv. Esophageal and esophagogastric junction cancer, or
    - v. Recurrent, progressive or metastatic cervical carcinoma, or
    - vi. Testicular cancer with progression after high dose chemotherapy or third-line therapy, **or**
    - vii. Unresectable or metastatic gallbladder cancer, or
    - viii. Unresectable or metastatic intrahepatic or extrahepatic cholangiocarcinoma, or
    - ix. Unresectable or metastatic breast cancer, or
    - x. Small bowel adenocarcinoma, or
    - xi. Resectable, borderline resectable, or metastatic pancreatic cancer, or
    - xii. Metastatic occult primary, or
    - xiii. Recurrent, progressive or metastatic squamous cell carcinoma of the vulva, or
    - xiv. Metastatic chondrosarcoma, or
    - xv. Metastatic chordoma, or
    - xvi. Widely metastatic Ewing sarcoma, or
    - xvii. Metastatic osteosarcoma, or
    - xviii. Recurrent or metastatic vaginal cancer, or
    - xix. Recurrent ovarian cancer.

Back to top

# Tumor Specific NPM1 Variant Analysis

- 1. Tumor specific *NPM1* variant analysis in hematological malignancies is considered **medically necessary** when:
  - A. The member has cytogenetically normal acute myeloid leukemia (AML).

#### Tumor Specific NRAS Variant Analysis

- 1. Tumor specific NRAS variant analysis in solid tumors is considered **medically necessary** when:
  - A. The member has suspected or proven metastatic colorectal cancer.

# Tumor Specific PIK3CA Variant Analysis

- 1. Tumor specific *PIK3CA* variant analysis in solid tumors is considered **medically necessary** when:
  - A. The member has a diagnosis of recurrent or stage IV, HR positive, HER2 negative invasive breast cancer.

Back to top


#### Tumor Specific TP53 Variant Analysis

- 1. Tumor specific *TP53* variant analysis in bone marrow or peripheral blood is considered **medically necessary** when:
  - A. The member has a diagnosis of:
    - i. Acute myeloid leukemia (AML), or
    - ii. Chronic lymphocytic leukemia (CLL), or
    - iii. Small lymphocytic leukemia (SLL), or
  - B. The member is undergoing diagnostic workup for mantle cell lymphoma (MCL).

Back to top

#### **HLA Typing For Transplantation**

- 1. HLA typing for transplantation is considered **medically necessary** when the member meets the following:
  - A. The member is being considered for any of the following:
    - Recipient of bone marrow transplantation, or
    - ii. Donor for bone marrow transplantation, **or**
    - iii. Recipient of solid organ transplantation, or
    - iv. Donor for solid organ transplantation.
- 2. HLA typing for transplantation is considered **investigational** for all other indications.



# Measurable (Minimal) Residual Disease (MRD) Analysis

### Hematologic Minimal Residual Disease (MRD) Testing

- 1. Measurable (minimal) residual disease analysis in bone marrow or peripheral blood is considered medically necessary when:
  - A. The member has a diagnosis of:
    - i. Acute Lymphocytic Leukemia (ALL), or
    - ii. Multiple Myeloma, or
    - iii. Chronic Lymphocytic Leukemia (CLL).

Back to top

# Evidence-Based Solid Tumor Minimal Residual Disease (MRD) Testing

- 1. Minimal residual disease (MRD) analysis for solid tumors using cell free DNA with sufficient evidence of clinical utility and validity is considered **medically necessary** when:
  - A. The identification of recurrent, refractory, or progressive disease will require a change in management, **and**
  - B. The member is not undergoing concurrent molecular laboratory testing for surveillance or monitoring for recurrent, refractory, or progressive disease, **and**
  - C. The member meets one of the following:
    - The member is currently being treated for cancer, and
      - a) The test has not previously been done for this cancer diagnosis, or
      - b) There is a clinical suspicion that the molecular profile of the member's tumor has changed, **or**
    - ii. The member is not currently being treated for their cancer, and
      - a) The test has not been done in the past 12 months, or
      - b) There is a clinical suspicion for tumor recurrence, and
  - D. The member meets one of the following:
    - i. The member is being tested via Guardant360 Response or Guardant Reveal **and** has one of the following:
      - a) Metastatic colon cancer, or
      - b) Colon cancer at any stage, and
        - (i) The member is being monitored for response to immune checkpoint inhibitor therapy, **or**
    - ii. The member is being tested via Signatera and has one of the following:
      - a) Metastatic colon cancer, **or**
      - b) Muscle invasive bladder cancer, or
      - c) Metastatic breast cancer, or
      - d) Any solid tumor, and
        - (i) The member is being monitored for response to immune checkpoint inhibitor therapy.
- 2. Minimal residual disease (MRD) analysis with sufficient evidence of clinical utility and validity using solid tumor tissue is considered **investigational** for all other indications where clinical utility and validity have not been demonstrated.

Back to top


#### **Emerging Evidence Solid Tumor Minimal Residual Disease (MRD) Testing**

1. Minimal residual disease (MRD) analysis with insufficient evidence of clinical validity using solid tumor tissue is considered **investigational**.

HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing

Back to top

- 1. Minimal residual disease analysis for HPV-related head and neck cancers using cell-free DNA is **medically necessary** when:
  - A. The member has a personal history of HPV-driven oropharyngeal cancer, and
  - B. The identification of recurrence or progression of disease will require a change in management, **and**
  - C. The member is not undergoing concurrent surveillance or monitoring for recurrence or progression by any other method, **and**
  - D. The member meets one of the following:
    - i. The member is currently being treated for HPV-driven oropharyngeal cancer, and
    - a) The test has not previously been done for this episode of cancer, **or**
    - ii. The member is not currently being treated for HPV-driven oropharyngeal cancer, and
      - a) The test has not been done in the past 12 months.



2. Minimal residual disease analysis using tumor tissue from HPV-related head and neck cancers is considered **investigational** for all other indications.

Back to top

#### **Tumor Mutational Burden (TMB)**

- Tumor mutational burden (TMB) testing is considered medically necessary when:
  - A. The member has a diagnosis of:
    - Recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, and
    - ii. The member has had progression of the cancer following prior treatment, and
    - iii. The member has no remaining satisfactory treatment options, and
  - B. The member does not have central nervous system cancer.

Back to top

# **Red Blood Cell Genotyping in Multiple Myeloma**

- 1. Red blood cell genotyping in individuals with multiple myeloma is considered **medically necessary** when:
  - A. The member has a diagnosis of multiple myeloma, and
  - B. The member is currently being treated or will be treated with either of the following:
    - i. Daratumumab (Darazalex), or
    - ii. Isatuximab (Sarclisa).

Back to top

#### **Cancer Exome and Genome Sequencing**

1. Cancer exome and genome sequencing in solid tumors and hematologic malignancies is considered **investigational**.

Back to top

#### **Genetic Testing to Confirm the Identity of Laboratory Specimens**

1. Genetic testing to confirm the identity of laboratory specimens (e.g., know error), when billed separately, is considered **investigational** because it is generally considered to be an existing component of the genetic testing process for quality assurance.


#### **Definitions**

- 1. **Tumor mutation burden:** A measurement of **mutations** carried by **tumor** cells and is a predictive biomarker that is being studied to evaluate its association with response to immunotherapy.
- 2. **Advanced cance**r: Cancer that is unlikely to be cured or controlled with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Treatment may be given to help shrink the tumor, slow the growth of cancer cells, or relieve symptoms.
- 3. **Myeloproliferative Neoplasms:** Rare overlapping blood diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets.

There are seven subcategories of myeloproliferative neoplasms:

- Chronic myeloid leukemia (CML)
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF)
- Essential thrombocytopenia (ET)
- Chronic neutrophilic leukemia
- Chronic eosinophilic leukemia
- Chronic eosinophilic leukemia-not otherwise specified
- MPN, unclassifiable (MPN-U)
- 4. **Myelodysplastic Syndromes (MDS):** A group of disorders characterized by abnormalities of the bone marrow, leading to low numbers of one or more types of blood cells. The WHO system recognizes 6 main types of MDS:
- MDS with multilineage dysplasia (MDS-MLD)
- MDS with single lineage dysplasia (MDS-SLD)
- MDS with ring sideroblasts (MDS-RS)
- MDS with excess blasts (MDS-EB)
- MDS with isolated del(5q)
- MDS, unclassifiable (MDS-U)
- 5. **Widely metastatic cancer**: Cancer for which local control cannot be delivered to all areas of disease (per National Comprehensive Cancer Care Network (NCCN))

#### **Products**



This information is for most, but not all, HealthPartners plans. Please read your plan documents to see if your plan has limits or will not cover some items. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage. These coverage criteria do not apply to Medicare Products. For more information regarding Medicare coverage criteria or for a copy of a Medicare coverage policy, contact Member Services at 952-883-7272 or 1-877-778-8384.

Approved Medical Director Committee 06/17/2021; Revised: 12/17/2021, 04/12/2022, 10/04/2022, 03/13/2023, 09/26/2023, 03/19/2024, 09/12/2024; Reviewed: 12/2021, 07/2022, 01/2023, 07/2023, 01/2024, 07/2024, 01/2025

#### References

- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2024. https://www.nccn.org/professionals/physician\_gls/pdf/nscl.pdf.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 4.2024. http://www.nccn.org/professionals/physician\_gls/PDF/colon.pdf.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/genetics\_colon.pdf.
- 4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2024. https://www.nccn.org/professionals/physician\_gls/pdf/breast.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/ovarian.pdf.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 3.2024 https://www.nccn.org/professionals/physician\_gls/pdf/mds.pdf
- 7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/pancreatic.pdf
- 8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors (GISTs). Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/gist.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/cutaneous\_melanoma.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/aml.pdf
- 11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/mastocytosis.pdf
- 12. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1.2024. https://www.nccn.org/professionals/physician\_gls/pdf/mpn.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/thyroid.pdf
- 14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Uterine Neoplasms. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/uterine.pdf
- 15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Chronic Myeloid Leukemia. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/cml.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Pediatric Acute Lymphoblastic Leukemia. Version 6.2024. https://www.nccn.org/professionals/physician\_gls/pdf/ped\_all.pdf
- 17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Acute Lymphoblastic Leukemia. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/all.pdf
- 18. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in B-Cell Lymphomas. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/b-cell.pdf
- 19. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Hairy Cell Leukemia. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/hairy\_cell.pdf
- 20. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Central Nervous System Cancers. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/cns.pdf
- 21. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020; 38(11):1222-1245. doi:10.1200/JCO.19.02960
- 22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2024. https://www.nccn.org/professionals/physician\_gls/pdf/prostate.pdf
- 23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/gastric.pdf
- 24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancer. Version .2024. https://www.nccn.org/professionals/physician\_gls/pdf/esophageal.pdf
- 25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/cll.pdf
- 26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/cervical.pdf
- 27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers. Version 3.2024. https://www.nccn.org/professionals/physician\_gls/pdf/hepatobiliary.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Occult Primary (Cancer of Unknown Primary [CUP]). Version 1.2025. https://www.nccn.org/professionals/physician\_gls/pdf/occult.pdf



- 29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 1.2024. https://www.nccn.org/professionals/physician\_gls/pdf/testicular.pdf
- 30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 4.2024. https://www.nccn.org/professionals/physician\_gls/pdf/myeloma.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Bowel Adenocarcinoma. Version 4.2024. https://www.nccn.org/professionals/physician\_gls/pdf/small\_bowel.pdf
- National Comprehensive Cancer Network. Biomarker Compendium. https://www.nccn.org/professionals/biomarkers/content/ Accessed 04/01/2024.
- 33. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/primary\_cutaneous.pdf
- Association for the Advancement of Blood and Biotherapies Association Bulletin #16-02: Mitigating the Anti-CD38
   Interference with Serologic Testing. (2016, January 15). https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab16-02.pdf
- 35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Histiocytic Neoplasms. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/histiocytic\_neoplasms.pdf
- 36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/sarcoma.pdf
- 37. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion [published correction appears in J Clin Oncol. 2022 Jun 20;40(18):2068]. J Clin Oncol. 2022;40(11):1231-1258. doi:10.1200/JCO.21.02767
- 38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Vulvar Cancer. Version 4.2024. https://www.nccn.org/professionals/physician\_gls/pdf/vulvar.pdf
- 39. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ampullary Adenocarcinoma. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/ampullary.pdf
- 40. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/bone.pdf
- 41. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 4.2024. https://www.nccn.org/professionals/physician\_gls/pdf/head-and-neck.pdf
- 42. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2024. https://www.nccn.org/professionals/physician\_gls/pdf/neuroendocrine.pdf
- 43. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Vaginal Cancer. Version 1.2025. https://www.nccn.org/professionals/physician\_gls/pdf/vaginal.pdf
- Merck & CO, Inc. KEYTRUDA (pembrolizumab). U.S. Food and Drug Administration. Website: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2020/125514s071s090lbl.pdf. Accessed 4/24/2024.
- Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MoIDX: Minimal Residual Disease Testing for Cancer (L38779). Available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38779
- 46. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58376). Available at: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleld=58376
- Viatte, MD, PhD, et al. Human leukocyte antigens (HLA): A roadmap. In: UpToDate, Connor RF (ed), Wolters Kluwer (Accessed on May 8, 2024). https://www.uptodate.com/contents/human-leukocyte-antigens-hla-a-roadmap
- 48. Negrin, R.S., MD, et al. Donor selection for hematopoietic cell transplantation. In: UpToDate, Connor, RF (ed), Wolters Kluwer (Accessed May 8, 2024). https://www.uptodate.com/contents/donor-selection-for-hematopoietic-cell-transplantation
- 2024 CONSULTATION GUIDELINES Recommended Timing for Transplant Consultation. Published jointly by NMDPSM and the American Society for Transplantation and Cellular Therapy (ASTCT). Available at: https://bethematchclinical.org/transplant-indications-and-outcomes/referral-timing-guidelines/
- 50. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19-47. doi:10.1097/TP.0b013e31827a19cc
- 51. "Requirements for Performing and Reporting HLA Typing" OTPN (Effective Date: 4/2/2024). Available at: https://optn.transplant.hrsa.gov/media/eavh5bf3/optn\_policies.pdf
- 52. FoundationOne CDx Technical Information (PMA approval number: P170019). US Food and Drug Administration. Website: https://www.accessdata.fda.gov/cdrh\_docs/pdf17/P170019C.pdf. Accessed 08/12/2024.
- 53. Minnesota statue 62Q.473 Biomarker Testing.
- 54. lowa statute 514C.36 Biomarker Testing.